Belite Bio Stock
Belite Bio, Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Yu-Hsin Lin
- Employees
- 41
- Market cap
- $5.7 B
- IPO
- 29/04/2022
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Belite Bio stock: price history
1D
-6.4%
1W
-7.6%
1M
-15.6%
6M
-13.7%
YTD
-10.7%
1Y
+60.3%
2Y
+155.1%
5Y
–
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~14% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Belite Bio stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Belite Bio
Analyst assessment of Belite Bio
PRICE TARGET LOW
US$206.00
CONSENSUS
US$245.83
MEDIAN
US$239.50
PRICE TARGET HIGH
US$303.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 15/10/2026
Belite Bio stock metrics
P/E
-51.73
P/B
7.39
EV/EBITDA
-49.92
RETURN ON EQUITY
-3.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
49.0%
FLOAT SHARES
19,551,320
AVG. DAILY VOLUME (30D)
200,950
Insider transactions (SEC)
Scholl Hendrik Peter
Scholl Hendrik Peter
Scholl Hendrik Peter
Scholl Hendrik Peter
Scholl Hendrik Peter
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Belite Bio stock
What does Belite Bio do?
Belite Bio, Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Yu-Hsin Lin, the company employs around 41 people.
The IPO was on 29/04/2022; the stock trades on NASDAQ under the ticker BLTE.
What do analysts say about Belite Bio stock?
6 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$245.83, ranging from US$206.00 to US$303.00, with a median of US$239.50.
This is an external assessment, not a statement by Market Jury.
When does Belite Bio report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 14% stronger than usual.
Does Belite Bio pay a dividend?
No, Belite Bio currently does not pay a dividend.
Which stocks are comparable to Belite Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Belite Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Belite Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.